Novartis had asked the justices to suspend a lower court's ruling that lifted a ban on generic versions of Gilenya, the Switzerland-based company's third highest-selling drug last year with $2.8 billion in sales. Exclusive-NHS drafts stricter oversight of trans youth care England's National Health Service has drafted new guidelines for treating transgender youth that would call for local authorities to be alerted in some cases where young people have obtained puberty blockers and hormone therapies on the private market, according to a copy of the guidelines reviewed by Reuters.
Read more about Health News Roundup: EU regulator endorses Takeda's dengue vaccine; Bavarian Nordic wins monkeypox vaccine order from Switzerland and more on Devdiscourse
Novartis had asked the justices to suspend a lower court's ruling that lifted a ban on generic versions of Gilenya, the Switzerland-based company's third highest-selling drug last year with $2.8 billion in sales. Exclusive-NHS drafts stricter oversight of trans youth care England's National Health Service has drafted new guidelines for treating transgender youth that would call for local authorities to be alerted in some cases where young people have obtained puberty blockers and hormone therapies on the private market, according to a copy of the guidelines reviewed by Reuters.
The U.S. Supreme Court on Thursday turned down Novartis bid to block the launch of generic versions of the company s blockbuster multiple sclerosis drug Gilenya in a dispute with China s HEC Pharm Co Ltd and other generic drugmakers.